Elutia Inc. Q4 2025 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy ELUT?
Source: seekingalpha
- Revenue Growth: Elutia Inc. reported $3.3 million in revenue for Q4 2025, marking a 16% increase from $2.8 million in the same quarter last year, indicating strong demand and an increase in market share in the breast reconstruction sector.
- Leadership Expansion: The appointment of Pete Ligotti as Chief Commercial Officer, with 30 years of experience at Integra and Nuvasive, is expected to enhance the company's market strategy and execution capabilities, driving product commercialization efforts.
- Regulatory Progress: The company has submitted its application for NXT-41 to the FDA, with clearance expected in the second half of 2025, and anticipates NXT-41x clearance by the end of the first half of 2027, providing a competitive edge in the breast reconstruction market.
- Strategic Focus Shift: Elutia's decision to concentrate resources on the NXT-41x program while reviewing SimpliDerm reflects the company's commitment to its core products and its responsiveness to market demands.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELUT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELUT
Wall Street analysts forecast ELUT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.070
Low
2.00
Averages
3.50
High
5.00
Current: 1.070
Low
2.00
Averages
3.50
High
5.00
About ELUT
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elutia Inc. Q4 2025 Earnings Call Insights
- Revenue Growth: Elutia Inc. reported $3.3 million in revenue for Q4 2025, marking a 16% increase from $2.8 million in the same quarter last year, indicating strong demand and an increase in market share in the breast reconstruction sector.
- Leadership Expansion: The appointment of Pete Ligotti as Chief Commercial Officer, with 30 years of experience at Integra and Nuvasive, is expected to enhance the company's market strategy and execution capabilities, driving product commercialization efforts.
- Regulatory Progress: The company has submitted its application for NXT-41 to the FDA, with clearance expected in the second half of 2025, and anticipates NXT-41x clearance by the end of the first half of 2027, providing a competitive edge in the breast reconstruction market.
- Strategic Focus Shift: Elutia's decision to concentrate resources on the NXT-41x program while reviewing SimpliDerm reflects the company's commitment to its core products and its responsiveness to market demands.
See More
Elutia (ELUT) Q4 2025 Earnings Call Transcript
See More
Elutia Reports Q4 Earnings with Mixed Results
- Revenue Performance: Elutia's Q4 net sales totaled $3.3 million, reflecting a 40% year-over-year decline, with SimpliDerm sales at $2.1 million and cardiovascular products at $1.2 million, indicating market challenges due to changes in distribution models.
- Profitability Improvement: Despite total operating expenses of $8.5 million, down from $8.8 million year-over-year, GAAP gross margin improved to 58.5%, while adjusted gross margin reached 66.8%, showcasing the company's efforts in cost control.
- Net Profit Turnaround: Elutia reported a net income of $70.8 million in Q4, significantly improving from a net loss of $9.1 million last year, primarily due to a $77.3 million gain from the sale of the BioEnvelope business, highlighting the success of its asset disposal strategy.
- Annual Financial Overview: For the full year 2025, net sales were $12.3 million, a 15.6% decline year-over-year, but net loss decreased from $45.3 million to $15.9 million, indicating improvements in ongoing operations and the initial effects of strategic adjustments.
See More
Elutia Regains Compliance with Nasdaq Listing Standards
- Compliance Restored: Elutia has successfully met Nasdaq's minimum bid price requirement, marking a significant advancement in compliance that enhances investor confidence and may attract more institutional investors.
- Market Value Met: The company also satisfied the minimum market value of listed securities requirement, ensuring its continued listing on Nasdaq, which could enhance its market image and brand value.
- Stock Price Surge: Following the restoration of compliance, Elutia's shares rose 6.5% in premarket trading, reflecting optimistic market sentiment towards the company's prospects and potentially supporting future financing and expansion efforts.
- Sales Outlook: Elutia anticipates Q4 net sales of $3.3 million, indicating stability and growth potential in the market, which may draw increased investor attention to its future performance.
See More
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
See More
Elutia Showcases NXT-41x Antibiotic-Eluting Biomatrix Technology
- Technological Advancement: Elutia will showcase its NXT-41x program at the Global BioInnovation Forum, aimed at addressing the postoperative infection complication rate of up to 25% in breast reconstruction, highlighting the potential of its biomatrix technology in clinical applications.
- Industry Demand: The development of this technology responds to the urgent needs in the breast reconstruction field, particularly given that one in three patients faces serious complications, underscoring Elutia's critical role in medical innovation.
- Leadership Team: CEO Randy Mills will present alongside Dr. Christopher Reid from UC San Diego Health, whose expertise in microsurgery and complex breast reconstruction will support the clinical application of the technology.
- Market Opportunity: Elutia's NXT-41x project builds on its validated biomatrix technology platform and aims to drive growth in the rapidly evolving medical device market by addressing unmet clinical needs.
See More
Elutia Inc. Q4 2025 Earnings Call Insights
- Revenue Growth: Elutia Inc. reported $3.3 million in revenue for Q4 2025, marking a 16% increase from $2.8 million in the same quarter last year, indicating strong demand and an increase in market share in the breast reconstruction sector.
- Leadership Expansion: The appointment of Pete Ligotti as Chief Commercial Officer, with 30 years of experience at Integra and Nuvasive, is expected to enhance the company's market strategy and execution capabilities, driving product commercialization efforts.
- Regulatory Progress: The company has submitted its application for NXT-41 to the FDA, with clearance expected in the second half of 2025, and anticipates NXT-41x clearance by the end of the first half of 2027, providing a competitive edge in the breast reconstruction market.
- Strategic Focus Shift: Elutia's decision to concentrate resources on the NXT-41x program while reviewing SimpliDerm reflects the company's commitment to its core products and its responsiveness to market demands.
See More
Elutia (ELUT) Q4 2025 Earnings Call Transcript
See More
Elutia Reports Q4 Earnings with Mixed Results
- Revenue Performance: Elutia's Q4 net sales totaled $3.3 million, reflecting a 40% year-over-year decline, with SimpliDerm sales at $2.1 million and cardiovascular products at $1.2 million, indicating market challenges due to changes in distribution models.
- Profitability Improvement: Despite total operating expenses of $8.5 million, down from $8.8 million year-over-year, GAAP gross margin improved to 58.5%, while adjusted gross margin reached 66.8%, showcasing the company's efforts in cost control.
- Net Profit Turnaround: Elutia reported a net income of $70.8 million in Q4, significantly improving from a net loss of $9.1 million last year, primarily due to a $77.3 million gain from the sale of the BioEnvelope business, highlighting the success of its asset disposal strategy.
- Annual Financial Overview: For the full year 2025, net sales were $12.3 million, a 15.6% decline year-over-year, but net loss decreased from $45.3 million to $15.9 million, indicating improvements in ongoing operations and the initial effects of strategic adjustments.
See More
Elutia Regains Compliance with Nasdaq Listing Standards
- Compliance Restored: Elutia has successfully met Nasdaq's minimum bid price requirement, marking a significant advancement in compliance that enhances investor confidence and may attract more institutional investors.
- Market Value Met: The company also satisfied the minimum market value of listed securities requirement, ensuring its continued listing on Nasdaq, which could enhance its market image and brand value.
- Stock Price Surge: Following the restoration of compliance, Elutia's shares rose 6.5% in premarket trading, reflecting optimistic market sentiment towards the company's prospects and potentially supporting future financing and expansion efforts.
- Sales Outlook: Elutia anticipates Q4 net sales of $3.3 million, indicating stability and growth potential in the market, which may draw increased investor attention to its future performance.
See More
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
See More
Elutia Showcases NXT-41x Antibiotic-Eluting Biomatrix Technology
- Technological Advancement: Elutia will showcase its NXT-41x program at the Global BioInnovation Forum, aimed at addressing the postoperative infection complication rate of up to 25% in breast reconstruction, highlighting the potential of its biomatrix technology in clinical applications.
- Industry Demand: The development of this technology responds to the urgent needs in the breast reconstruction field, particularly given that one in three patients faces serious complications, underscoring Elutia's critical role in medical innovation.
- Leadership Team: CEO Randy Mills will present alongside Dr. Christopher Reid from UC San Diego Health, whose expertise in microsurgery and complex breast reconstruction will support the clinical application of the technology.
- Market Opportunity: Elutia's NXT-41x project builds on its validated biomatrix technology platform and aims to drive growth in the rapidly evolving medical device market by addressing unmet clinical needs.
See More
